CVS Health Corporation (CVS) Stock Price & Analysis
CVS Health Corporation (CVS) closed at USD 94.48 on Thursday, October 22, 2026, up 1.83% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 92.79; the Oct 22, 2026 session ranged USD 92.49–94.84 on volume of 7,224,667 shares. Market capitalization is $120.84B, with a 52-week range of USD 69.51–110.68 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CVS.md
Key facts (CVS)
- Last four reported quarters (through Jun 30, 2026): revenue $415B, net income $4.89B (1.2% margin), free cash flow $11.8B (SEC filings).
- Valuation: P/E 24.7x (avg 27.2x at the last 3 fiscal year-ends), EV/EBITDA 13.0x, net debt $45.5B.
- 10 of 80 tracked superinvestors hold CVS (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 1 new, 1 added, 6 reduced, 2 unchanged.
- Analysts: Buy (mean 1.81 on a 1–5 scale) (27 analysts), mean target USD 115.48 (range 103–145).
- Total return with dividends: 1Y +20.1% vs S&P 500 +14.9%; 5Y +27.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 1.65, revenue estimate $105B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CVS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $292B | $322B | $358B | $373B | $402B | $415B |
| Gross profit | $116B | $126B | $141B | $167B | $181B | — |
| Operating income | $13.3B | $7.95B | $13.7B | $8.52B | $4.66B | $8.29B |
| Net income | $8.00B | $4.31B | $8.34B | $4.61B | $1.77B | $4.89B |
| EPS (diluted) | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 | — |
| Free cash flow | $15.7B | $13.4B | $10.4B | $6.33B | $7.81B | $11.8B |
| Gross margin | 39.8% | 38.9% | 39.3% | 44.7% | 45.0% | — |
| Operating margin | 4.6% | 2.5% | 3.8% | 2.3% | 1.2% | 2.0% |
| Net margin | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% | 1.2% |
| Revenue growth | +8.7% | +10.4% | +10.9% | +4.2% | +7.8% | — |
| Cash + short-term investments | $12.5B | $15.7B | $11.5B | $11.0B | $10.6B | — |
| Total debt | $56.2B | $52.3B | $58.8B | $62.6B | $60.5B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CVS)
P/E 24.7x · P/S 0.3x · EV/EBITDA 13.0x · EV/Sales 0.4x · P/FCF 10.3x · P/B 1.5x · FCF yield 9.73% · Earnings yield 4.05% · Dividend yield (paid, TTM) 2.83% · Net debt $45.5B · EV $166B
P/E at fiscal year-ends: Dec 2025 57.1x, Dec 2024 12.3x, Dec 2023 12.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (CVS)
10 of 80 tracked investors hold CVS (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Prem Watsa | Fairfax Financial Holdings | 10.63% | $281M | Unchanged | Q2 2026 |
| Christopher Davis | Davis Advisors | 5.27% | $1.23B | Reduced -3.0% | Q2 2026 |
| Samantha McLemore | Patient Capital Management | 4.25% | $128M | Reduced -9.0% | Q2 2026 |
| Hillman Capital | Hillman Capital Management | 4.15% | $5.7M | Reduced -17.8% | Q2 2026 |
| Richard Pzena | Pzena Investment Management | 3.57% | $1.22B | Reduced -14.6% | Q2 2026 |
| Dodge & Cox Funds | Dodge & Cox | 2.71% | $5.17B | Reduced -3.4% | Q2 2026 |
| Viking Global | Viking Global Investors | 1.08% | $379M | New position | Q2 2026 |
| John Rogers | Ariel Investments | 0.75% | $75.5M | Added +4.0% | Q2 2026 |
| Bill Nygren | Oakmark Funds | 0.05% | $34.7M | Reduced -32.0% | Q2 2026 |
| David Katz | Matrix Asset Advisors | 0.04% | $529K | Unchanged | Q3 2026 |
Analysts (CVS)
Consensus Buy (mean 1.81 on a 1–5 scale), 27 analysts; mean target USD 115.48 (low 103, high 145).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Leerink Partners | Target lowered | Outperform | $119 → $112 |
| 2026-09-03 | UBS | Target lowered | Buy | $126 → $118 |
| 2026-08-19 | Argus Research | Target raised | Buy | $104 → $114 |
| 2026-08-12 | JP Morgan | Target raised | Overweight | $111 → $118 |
| 2026-08-06 | UBS | Target raised | Buy | $122 → $126 |
| 2026-08-06 | Evercore ISI Group | Target lowered | Outperform | $130 → $125 |
| 2026-08-06 | Barclays | Target raised | Overweight | $106 → $108 |
| 2026-07-25 | UBS | Target raised | Buy | $115 → $122 |
| 2026-07-14 | Truist Securities | Target raised | Buy | $108 → $118 |
| 2026-07-13 | Wells Fargo | Target raised | Overweight | $103 → $123 |
| 2026-07-09 | RBC Capital | Target raised | Outperform | $107 → $113 |
| 2026-07-07 | Cantor Fitzgerald | Target raised | Overweight | $100 → $110 |
Total return (dividends reinvested) (CVS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +20.1% | +27.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +20.2% | +5.0% |
| Volatility (annualized) | 32.1% | 31.1% |
| Max drawdown | -22.6% (Jul 2026→Sep 2026) | -55.6% (Jan 2022→Dec 2024) |
Companies that name CVS in their SEC reports
| Relationship to CVS | Company | Filing | Sentence |
|---|---|---|---|
| partner | SelectQuote, Inc. (SLQT) | 10-K Aug 25, 2026 | “We have also formed partnerships with several pharmacy benefit managers including OptumRx, Caremark CVS, and Express Scripts, which help support SelectRx, as well as several providers of health-related resources that support improved health outcomes as partners for Healthcare Select.” |
| supplier | CARDINAL HEALTH INC (CAH) | 10-K Aug 11, 2026 | “Our largest customer, CVS Health, accounted for 28 percent of our fiscal 2026 revenue.” |
| supplier | MCKESSON CORP (MCK) | 10-K May 8, 2026 | “Sales to our largest customer, CVS Health Corporation ("CVS"), accounted for approximately 24% of our total consolidated revenues in fiscal 2026.” |
| supplier | Arrive AI Inc. (ARAI) | 10-K Apr 15, 2026 | “like FedEx and UPS and retailers like Walmart and CVS have automation efforts underway as well but they are prospective customers for” |
| competitor | NextPlat Corp (NXPL) | 10-K Mar 31, 2026 | “In the Specialty Pharmacy Services segment, we compete with several national and regional specialty pharmacy companies that have substantial financial resources and which also provide products and services to the chronically ill, such as CVS Caremark, Express Scripts, Humana, Optum and Walgreens.” |
| supplier | FITLIFE BRANDS, INC. (FTLF) | 10-K Mar 31, 2026 | “Irwin's largest mass market customers are CVS, Walmart, Walgreens, and Costco Canada.” |
| partner | GIFTIFY, INC. (GIFT) | 10-K Mar 18, 2026 | “branded exchange partnership with CVS Pharmacy in 2012 and saw increased spending from both new and existing customers.” |
| competitor | DocGo Inc. (DCGO) | 10-K Mar 16, 2026 | “Major competitors (in each case relative to only some of our products or services) include much larger, national or regional telehealth or in-home healthcare service providers such as DispatchHealth, Modivcare, Option Care Health, Teladoc, Amwell, Signify Health (acquired by CVS in March 2023), MedArrive, Biofourmis and One Medical (acquired by Amazon in February 2023).” |
| competitor | BrightSpring Health Services, Inc. (BTSG) | 10-K Feb 27, 2026 | “In our infusion and specialty pharmacy services, we compete in the large and fragmented home infusion and specialty pharmacy markets including Option Care Health, Inc., Coram CVS/specialty infusion services (a division of CVS Health), Accredo Health Group, Inc. (a unit of Cigna), Optum Specialty Pharmacy (a subsidiary of OptumRx, which is a unit of the UnitedHealth Group), and various regional and local providers.” |
| partner | Amneal Pharmaceuticals, Inc. (AMRX) | 10-K Feb 27, 2026 | “For example, large wholesalers and retailer customers have formed alliances, such as Walgreens and Cencora, Inc., Rite Aid and McKesson Drug Company, and CVS Caremark and Cardinal Health.” |
| partner | ANI PHARMACEUTICALS INC (ANIP) | 10-K Feb 27, 2026 | “We have contracts with several major distributors in the U.S., including Anda, Smith Drug Company, Morris Dickson, CVS Caremark, Accredo, OptumRx, CuraScript and several other partners.” |
| supplier | BRINKS CO (BCO) | 10-K Feb 26, 2026 | “CVS services are provided to customers throughout the world.” |
| supplier | UNITED THERAPEUTICS Corp (UTHR) | 10-K Feb 25, 2026 | “In the United States, we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty.” |
| competitor | Option Care Health, Inc. (OPCH) | 10-K Feb 24, 2026 | “The Company's competitors within the home infusion market include Optum Infusion Pharmacy (a unit of UnitedHealth Group), Coram CVS/specialty infusion services (a division of CVS Health), Amerita Specialty Pharmacy (a division of BrightSpring Health), KabaFusion, Soleo Health, Vital Care and many other regional and local home infusion companies, ambulatory infusion centers, or specialty pharmacies including Accred…” |
| competitor | AdaptHealth Corp. (AHCO) | 10-K Feb 24, 2026 | “In addition, AdaptHealth competes with non-HME providers, including CVS and Amazon.” |
CVS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.65 | $1.71 | -3.6% | $104.80B | 23 |
| Next quarter (ends Dec 2026) | $1.24 | $1.33 | -6.4% | $106.96B | 23 |
| Current fiscal year (ends Dec 2026) | $8.04 | $7.44 | +8.0% | $418.04B | 25 |
| Next fiscal year (ends Dec 2027) | $8.54 | $8.41 | +1.5% | $430.06B | 26 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 94.48 |
|---|---|
| Change | ▲ 1.83% (up) |
| Previous Close | USD 92.79 |
| Open | USD 93.08 |
| Day Range | USD 92.49 – 94.84 |
| 52-Week Range | USD 69.51 – 110.68 |
| Volume | 7,224,667 shares |
| Market Cap | $120.84B |
| Exchange | NYQ |
Technical Analysis (CVS)
Nexqual's technical model rates CVS "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.9 (neutral) |
| vs SMA50 | Above (USD 91.64) |
| MACD | 0.69 (positive) |
Analyst Ratings (CVS)
Wall Street analysts rate CVS "Buy" based on 27 analysts, with a mean price target of USD 115.48 (range USD 103–145), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 115.48 |
| High Target | USD 145 |
| Low Target | USD 103 |
| Buy / Hold / Sell | 25 / 2 / 0 |
Earnings (CVS)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 1.65 |
| Revenue Estimate | $104.80B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.58 vs est 1.85 ▲ beat |
| 2026-03-31 | USD 2.57 vs est 2.21 ▲ beat |
| 2025-12-31 | USD 1.09 vs est 1 ▲ beat |
| 2025-09-30 | USD 1.6 vs est 1.36 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (CVS)
| Total Revenue | $412.64B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +7.10% |
| Gross Margin | +13.65% |
| Operating Margin | +3.86% |
| Profit Margin | +1.18% |
| ROE | +6.21% |
| Debt / Equity | 0.96 |
| Current Ratio | 0.87 |
| Total Cash | $13.96B |
| Total Debt | $76.31B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $11.76B (2.8% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (CVS)
Nexqual rates CVS Health Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 14%, operating 4% (last 12 months) |
| Balance Sheet | Weak — $14.0B cash and investments vs $59.5B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $11.8B (last 4 quarters to Jun 2026, SEC), slim 2.8% margin |
| Efficiency | Mixed — ROE 6%, ROA 3.0% |
Ownership (CVS)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +91.06% |
| Shares Outstanding | 1.28B |
| Float | 1.28B |
| Short % of Float | +1.30% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (CVS)
CVS Health Corporation is led by J. David Joyner CEBS, CEO, President & Chairman, per Nexqual as of October 23, 2026 at 09:26 UTC.
| CEO, President & Chairman | J. David Joyner CEBS |
|---|---|
| Executive VP & CFO | Brian O. Newman |
| Executive VP & Group President | Prem S. Shah Pharm.D |
| Executive VP & President of Aetna | Steven Hale Nelson |
Major Backers & Investors (CVS)
Notable institutional backers of CVS Health Corporation include Capital Group, Dodge & Cox Inc., Wellington Management, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 7.76% |
| Dodge & Cox Inc. | 3.91% |
| Wellington Management | 2.64% |
| WASHINGTON MUTUAL INVESTORS FUND | 2.47% |
| FMR, LLC | 2.26% |
| Income Fund of America | 1.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.63% |
| Vanguard Group | 8.59% |
| State Street | 4.71% |
| Geode Capital | 2.34% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELV | Elevance Health, Inc. | USD 445.28 | ▲ 2.57% |
| CI | The Cigna Group | USD 315.88 | ▲ 3.78% |
| HUM | Humana Inc. | USD 420.97 | ▼ 1.05% |
| UNH | UnitedHealth Group Incorporated | USD 424.98 | ▲ 1.91% |
| CNC | Centene Corporation | USD 71.24 | ▲ 1.42% |
| MOH | Molina Healthcare Inc | USD 216.64 | ▲ 0.81% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt